Molina ÁN, Dotres MC, Legarreta PE, Vega MD, Piedra BM

Language: Spanish
References: 29
Page: 29-38
PDF size: 182.91 Kb.

ABSTRACT

Introduction: there has been pointed the importance of knowing the behavior of the pneumococcal disease and the isolated serogroups in order to take significant actions favoring our population´s health and especially that of our children.
Objectives: to describe the behavior of the pneumococcal disease and the isolated serogroups by age group from 2009 to 2015.
Methods: a retrospective study was conducted to find out the incidence of cases according to the above-mentioned illnesses by age groups, and the identification of pneumococci; percentages were estimated, and the sentinel study database was used.
Results: the age groups with the highest incidence were younger than one year and one to four years-old; the prevailing serogroups were 14, 19A and 6B; the highest number of disease notifications occurred from February to April, and blood culture and pleural fluid represented over 50 % of isolates.
Conclusions: the pneumococcal disease is an illness of great morbidity in our hospital, which mainly affects children younger than 5 years, hence one should insist on the surveillance and detection of this disease.

REFERENCES

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375:1969-87.

2. Espín MI, Sandoval A, Ruiz J, Navarro JA, García J, Pérez Flores D. Enfermedad neumocócica invasiva en niños de la Región de Murcia. Gac Sanit. 2002;16(5):385-91.

3. Weber DJ, Rutala WA. Streptococcus pneumoniae infections: microbiology, epidemiology, treatment, and prevention. Medscape [homepage en Internet]; 2003 [citado 15 de Febrero de 2016]. Disponible en: http://cme.medscape.com/viewarticle/451448

4. Ladhani S, Slack MPE, Heath PT, von Gottberg A, Chandra M, Ramsay ME, et al. Invasive Haemophilus influenzae disease, Europe, 1996-2006. Emerg Infect Dis. 2010;16(3):455-83.

5. Tully J, Viner RM, Coen PG, Stuart JM, Zambon M, Peckham C, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-50.

6. OPS. Proyecto de Prevención y Control de Enfermedades Transmisibles; Washington D.C., Julio de 2011 (Guía operativa para la vigilancia nacional intensificada de infección respiratoria aguda grave [IRAG]).

7. Fernández SB, Uribe RV. Mortalidad por neumonías en niños menores de cinco años. Boletín Médico del Hospital Infantil de México. 2010;67(6):567-9.

8. Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, et al. Cost-utility analysis of 10 and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31:2839-47.

9. OMS. Meeting report pneumococcal vaccines WHO position paper-2012- recommendations. Vaccine. 2012;30:4717-8.

10. Dotres CP, Puga R, Ricardo Y, Broño CR, Paredes B, Echemendía V, et al. Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: A randomized phase I clinical trial. Vaccine. 2014;32:5266-70.

11. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, Mc Call N, et al. The global burden of disease due to Streptococcus pneumoniae in children less than 5 years of age. Lancet. 2009;374:893-902.

12. Toraño G, Menéndez D, Llop A, Dickinson F, Varcárcel M, Capote M, Pinto N. Haemophilus influenzae: caracterización de aislamientos recuperados de enfermedades invasivas en Cuba en el período 2008-2011. Vaccimonitor. 2012;21(3):26-31.

13. Papavasileiou K, Papavasileiou E, Tzanakaki G, Voyatzi A, Kremastinou J, Chatzipanagiotou S. Acute Bacterial Meningitis Cases Diagnosed by Culture and PCR in a Children's Hospital Throughout a 9-Year Period (2000-2008) in Athens, Greece. Mol Diagn Ther. 2011;15(2):109-13.

14. Sanchén A, Rodríguez OI, Torres LD, Cordero M. Caracterización epidemiológica y microbiológica de las meningoencefalitis bacterianas en la provincia de Camagüey. Arch Med Camagüey [serie en Internet]. 2010 [citado 16 de Febrero de 2016];14(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025- 02552010000300013&lng=es&nrm=iso&tlng=es

15. Ba O, Fleming JA, Dieye Y, Mutombo B, Ba M, Fafa M. Hospital surveillance of childhood bacterial meningitis in Senegal and the introduction of Haemophilus influenzae type b conjugate vaccine. Am J Trop Med Hyg. 2010;83(6):1330-5.

16. Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis. 2010;10:32-42.

17. Grenón SL, Salvi Grabulosa MC, Regueira MM, Fossati MS, von Specht MH. Meningitis neumocócica en niños menores de 15 años. Dieciséis años de vigilancia epidemiológica en Misiones, Argentina. Rev Argent Microbiol. 2014;(46)1:23.

18. Arguedas A, Abdelnour A, Soley C, Jimenez E, Jimenez AL, Ramcharran D, et al. Prospective epidemiologic surveillance of invasive pneumococcal disease and pneumonia in children in San José, Costa Rica. Vaccine. 2012;30(13):2342-8.

19. OMS. Initiative for vaccine research: bacterialinfections. Geneva: WHO; 2009.

20. Castañeda E, Agudelo C, Regueira M, Corso A, de Cunto Brandileone M, Brandão A, et al. Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: ASIREVA II Project, 2000-2005. Pediatr Infect Dis J. 2009;28(9):265-70.

21. González Martínez F, Saavedra Lozano J, Navarro Gómez ML, Santos Sebastián MM, Rodríguez Fernández R, González Sánchez M, et al. Aumento de la incidencia de enfermedad neumocócica invasora producida por el serotipo 19A previo a la introducción de las vacunas neumocócicas ampliadas. An Pediatr (Barc). 2013;79(5):288-92.

22. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: Impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197-209.

23. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Del Castillo F, Hernández-Sampelayo T, et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol. 2011;18:89-94.

24. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect Dis. 2010;10:90.

25. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. The Lancet. 2012;6736(12):61854-6.

26. López E. Sociedad Argentina de Infectología Pediátrica [homepage en Internet]; Al Día, Buenos Aires, junio 10/2010 [citado 7 de Marzo de 2016]. Disponible en: http://boletinaldia.sld.cu/aldia/2010/06/12/presentan-en-argentina-vacuna-contrainfecciones- neumococicas

27. Gessner BD, Mueller JE, Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. BMC Infect Dis. 2010;10:22.

28. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine- United States, 2007. MMWR Morb Mortal Wkly Rep. 2010;59:253-7.

29. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: Use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126:186-90.